Trial: 201809022

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma

Phase

III

Principal Investigator

Ansstas, George

Disease Site

Melanoma, Skin

Learn more about this study at: clinicaltrials.gov